Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Transplant. Jun 18, 2026; 16(2): 118702
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118702
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118702
Glucagon-like peptide-1 agonists usage to widen the living donor pool for liver transplantation: A novel metabolic strategy
Amr Alnagar, Department of General Surgery, University Hospitals of Birmingham, Birmi
Muhammad U Khan, Mahmoud Mersal, Mohamed Ayyad, Department of Upper GIT Surgery, University Hospitals of Birmingham, Birmingham B9 5SS, United Kingdom
Muhammad S Ahmad, Department of General Surgery, The Dudley Group NHS Foundation Trust, Dudley DY1 2HQ, United Kingdom
Rana Hassan, Department of Gyneacology, Ras Elteen Hospital, Alexandria 21532, Egypt
Mohamed Saleem Noormohamed, Department of Upper GIT Surgery, Worcestershire Acute Hospitals, Worcester WR5 1DD, United Kingdom
Author contributions: Alnagar A designed the study, Khan MU, Ahmad MS, Mersal M, Ayyad M, and Hassan R conducted the literature review and wrote the manuscript draft; Noormohamed MS performed the critical revision and final drafting of the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
AI contribution statement: ChatGPT was used for language polishing and editing, not for scientific content, image generation or study design.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Amr Alnagar, PhD, Ms, MRCS, Department of General Surgery, University Hospitals of Birmingham, 6 Chamberlain Road, Birmingham B9 5SS, United Kingdom. amr.alnagar@nhs.net
Received: January 9, 2026
Revised: January 27, 2026
Accepted: March 2, 2026
Published online: June 18, 2026
Processing time: 140 Days and 21.2 Hours
Revised: January 27, 2026
Accepted: March 2, 2026
Published online: June 18, 2026
Processing time: 140 Days and 21.2 Hours
Core Tip
Core Tip: The use of glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists for weight loss is expanding, particularly as bridging therapies for living donors in liver transplantation. High body mass index donors are often declined due to safety concerns, but weight reduction can improve surgical outcomes and reduce morbidity and mortality. There is growing clinical evidence supporting these agents to minimize perioperative complications. However, they should be used cautiously due to potential side effects like delayed gastric emptying and aspiration risks.